You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 7,727,994

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,727,994

Title:	Methods of treating patients suffering from movement disorders
Abstract:	The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A.sub.2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A.sub.2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A.sub.2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A.sub.2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
Inventor(s):	Kase; Hiroshi (Tokyo, JP), Mori; Akihisa (Chiba, JP), Waki; Yutaka (Princeton, NJ), Ohsawa; Yutaka (London, GB), Karasawa; Akira (Shizuoka, JP), Kuwana; Yoshihisa (Shizuoka, JP)
Assignee:	Kyowa Hakko Kirin Co., Ltd. (Tokyo, JP)
Application Number:	11/326,516
Patent Claims:	1. A method of prolonging effective treatment of Parkinson's disease, comprising administering to a patient in need thereof (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine, in an amount effective to delay the patient's need for add-on L-DOPA therapy, wherein the patient currently receives L-DOPA therapy. 2. The method according to claim 1 wherein the development of motor complications is delayed. 3. The method according to claim 1 wherein the patient does not have subsequent administration of L-DOPA.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.